The system uses artificial intelligence for image reconstruction to improve diagnostic precision and workflow efficiency in radiology, cardiology, and oncology.
Philips received Food and Drug Administration (FDA) 510(k) clearance for its Verida system, an artificial intelligence (AI)-powered detector-based spectral computed tomography (CT) system.
The system integrates AI-based reconstruction into the imaging chain and features a third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction. This design aims to enhance image quality across various clinical applications while allowing clinicians to customize image de-noising based on preference, according to a Philips press release.
“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets,” says Dan Xu, business leader of CT at Philips, in a release. “By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”
Workflow and Efficiency Improvements
Built on detector-based technology, the system enables always-on spectral imaging without the need for separate scans or workflow modifications. Verida includes updated computing infrastructure and software enhancements to the spectral result generation pipeline to improve performance and usability.
The system reconstructs 145 images per second, allowing entire exams to appear in less than 30 seconds. This is twice as fast as previous iterations and supports a capacity of up to 270 exams daily, according to the company.
By capturing both high- and low-energy data in a single acquisition, clinicians can access conventional and spectral results at the same time. This approach supports material differentiation and tissue characterization without requiring pre-selection or repeat scans.
Clinical Applications
The Verida system is intended for diagnostic imaging in radiology, interventional radiology, and cardiology. It is also used in oncology for treatment preparation and radiation therapy planning. The FDA clearance covers head, whole body, cardiac, and vascular CT applications for patients of all ages.
Additionally, the system is indicated for low-dose CT lung cancer screening when performed within established protocols. Respiratory correlated scanning and extended field-of-view images are intended for radiation therapy planning and simulation use only, according to the press release.
Photo caption: Verida
Photo credit: Philips
